BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

941 related articles for article (PubMed ID: 21653605)

  • 1. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
    Riera E; Cabot G; Mulet X; García-Castillo M; del Campo R; Juan C; Cantón R; Oliver A
    J Antimicrob Chemother; 2011 Sep; 66(9):2022-7. PubMed ID: 21653605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates.
    El Amin N; Giske CG; Jalal S; Keijser B; Kronvall G; Wretlind B
    APMIS; 2005 Mar; 113(3):187-96. PubMed ID: 15799762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential.
    Mushtaq S; Ge Y; Livermore DM
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3086-92. PubMed ID: 15273124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of carbapenem resistance in non-metallo-beta-lactamase-producing clinical isolates of Pseudomonas aeruginosa from a Tunisian hospital.
    Hammami S; Ghozzi R; Burghoffer B; Arlet G; Redjeb S
    Pathol Biol (Paris); 2009; 57(7-8):530-5. PubMed ID: 18977099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.
    Davies TA; Marie Queenan A; Morrow BJ; Shang W; Amsler K; He W; Lynch AS; Pillar C; Flamm RK
    J Antimicrob Chemother; 2011 Oct; 66(10):2298-307. PubMed ID: 21775338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spread of efflux pump-overexpressing, non-metallo-beta-lactamase-producing, meropenem-resistant but ceftazidime-susceptible Pseudomonas aeruginosa in a region with blaVIM endemicity.
    Pournaras S; Maniati M; Spanakis N; Ikonomidis A; Tassios PT; Tsakris A; Legakis NJ; Maniatis AN
    J Antimicrob Chemother; 2005 Oct; 56(4):761-4. PubMed ID: 16115825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OprD mutations and inactivation, expression of efflux pumps and AmpC, and metallo-β-lactamases in carbapenem-resistant Pseudomonas aeruginosa isolates from South Korea.
    Lee JY; Ko KS
    Int J Antimicrob Agents; 2012 Aug; 40(2):168-72. PubMed ID: 22633564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study.
    Cabot G; Ocampo-Sosa AA; Tubau F; Macia MD; Rodríguez C; Moya B; Zamorano L; Suárez C; Peña C; Martínez-Martínez L; Oliver A;
    Antimicrob Agents Chemother; 2011 May; 55(5):1906-11. PubMed ID: 21357294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A highly carbapenem-resistant Pseudomonas aeruginosa isolate with a novel blaVIM-4/blaP1b integron overexpresses two efflux pumps and lacks OprD.
    Maniati M; Ikonomidis A; Mantzana P; Daponte A; Maniatis AN; Pournaras S
    J Antimicrob Chemother; 2007 Jul; 60(1):132-5. PubMed ID: 17483142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries.
    Castanheira M; Deshpande LM; Costello A; Davies TA; Jones RN
    J Antimicrob Chemother; 2014 Jul; 69(7):1804-14. PubMed ID: 24603963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.
    Valenza G; Seifert H; Decker-Burgard S; Laeuffer J; Morrissey I; Mutters R;
    Int J Antimicrob Agents; 2012 Mar; 39(3):255-8. PubMed ID: 22230334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational inactivation of OprD in carbapenem-resistant Pseudomonas aeruginosa isolates from Korean hospitals.
    Kim CH; Kang HY; Kim BR; Jeon H; Lee YC; Lee SH; Lee JC
    J Microbiol; 2016 Jan; 54(1):44-49. PubMed ID: 26727901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Chinese hospitals.
    Wang J; Zhou JY; Qu TT; Shen P; Wei ZQ; Yu YS; Li LJ
    Int J Antimicrob Agents; 2010 May; 35(5):486-91. PubMed ID: 20185276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The roles of active efflux system overexpression and outer membrane protein OprD deficiency or loss in carbapenem resistance of Pseudomonas aeruginosa].
    Yi MY; Wang PY; Huang HJ; Liu YC
    Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(7):457-62. PubMed ID: 16677571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metallo-β-lactamase-production in meropenem-susceptible Pseudomonas aeruginosa isolates: risk for silent spread.
    Picão RC; Carrara-Marroni FE; Gales AC; Venâncio EJ; Xavier DE; Tognim MC; Pelayo JS
    Mem Inst Oswaldo Cruz; 2012 Sep; 107(6):747-51. PubMed ID: 22990963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo evolution of resistance of Pseudomonas aeruginosa strains isolated from patients admitted to an intensive care unit: mechanisms of resistance and antimicrobial exposure.
    Solé M; Fàbrega A; Cobos-Trigueros N; Zamorano L; Ferrer-Navarro M; Ballesté-Delpierre C; Reustle A; Castro P; Nicolás JM; Oliver A; Martínez JA; Vila J
    J Antimicrob Chemother; 2015 Nov; 70(11):3004-13. PubMed ID: 26260130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efflux system overexpression and decreased OprD contribute to the carbapenem resistance among extended-spectrum beta-lactamase-producing Pseudomonas aeruginosa isolates from a Chinese university hospital.
    Liu Y; Li XY; Wan LG; Jiang WY; Li FQ; Yang JH
    Microb Drug Resist; 2013 Dec; 19(6):463-8. PubMed ID: 23865862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations of OprD in carbapenem-intermediate and -susceptible strains of Pseudomonas aeruginosa isolated from patients with bacteremia in a Spanish multicenter study.
    Ocampo-Sosa AA; Cabot G; Rodríguez C; Roman E; Tubau F; Macia MD; Moya B; Zamorano L; Suárez C; Peña C; Domínguez MA; Moncalián G; Oliver A; Martínez-Martínez L;
    Antimicrob Agents Chemother; 2012 Apr; 56(4):1703-13. PubMed ID: 22290967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa.
    Tam VH; Chang KT; LaRocco MT; Schilling AN; McCauley SK; Poole K; Garey KW
    Diagn Microbiol Infect Dis; 2007 Jul; 58(3):309-14. PubMed ID: 17617302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Carbapenem resistance determined by metalloenzymes in clinical isolates of Pseudomonas aeruginosa].
    Sánchez A; Salso S; Culebras E; Picazo JJ
    Rev Esp Quimioter; 2004 Dec; 17(4):336-40. PubMed ID: 15696224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.